We’ve recently updated our valuation analysis.

Theriva Biologics Valuation

Is TOVX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TOVX?

Other financial metrics that can be useful for relative valuation.

TOVX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does TOVX's PB Ratio compare to its peers?

The above table shows the PB ratio for TOVX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.1x
LIXT Lixte Biotechnology Holdings
4.2xn/aUS$12.3m
IMNN Imunon
0.3x40.4%US$11.2m
BRTX BioRestorative Therapies
0.7x28.0%US$11.1m
IPIX Innovation Pharmaceuticals
3.1xn/aUS$10.6m
TOVX Theriva Biologics
0.2xn/aUS$13.6m

Price-To-Book vs Peers: TOVX is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (2.1x).


Price to Earnings Ratio vs Industry

How does TOVX's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.0%
n/an/an/a

Price-To-Book vs Industry: TOVX is good value based on its Price-To-Book Ratio (0.2x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is TOVX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TOVX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TOVX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of TOVX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TOVX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TOVX's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TOVX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.90
US$5.50
+511.1%
27.3%US$7.00US$4.00n/a2
Jan ’24US$0.45
US$5.50
+1,109.3%
27.3%US$7.00US$4.00n/a2
Dec ’23US$0.72
US$5.50
+663.9%
27.3%US$7.00US$4.00n/a2
Nov ’23US$0.78
US$5.50
+608.8%
27.3%US$7.00US$4.00n/a2
Oct ’23US$0.99
US$6.00
+508.5%
33.3%US$8.00US$4.00n/a2
Sep ’23US$1.47
US$6.00
+308.2%
33.3%US$8.00US$4.00n/a2
Aug ’23US$1.37
US$16.25
+1,086.1%
38.5%US$22.50US$10.00n/a2
Jul ’23US$2.30
US$16.25
+606.5%
38.5%US$22.50US$10.00n/a2
Jun ’23US$2.26
US$16.25
+619.0%
38.5%US$22.50US$10.00n/a2
May ’23US$2.39
US$16.25
+580.2%
38.5%US$22.50US$10.00n/a2
Apr ’23US$2.88
US$16.25
+464.8%
38.5%US$22.50US$10.00n/a2
Mar ’23US$2.44
US$11.25
+361.8%
11.1%US$12.50US$10.00n/a2
Feb ’23US$2.60
US$13.75
+429.0%
9.1%US$15.00US$12.50n/a2
Jan ’23US$2.72
US$13.75
+405.1%
9.1%US$15.00US$12.50US$0.452
Dec ’22US$3.35
US$13.75
+310.4%
9.1%US$15.00US$12.50US$0.722
Nov ’22US$4.33
US$18.75
+332.8%
33.3%US$25.00US$12.50US$0.782
Oct ’22US$4.54
US$18.75
+312.9%
33.3%US$25.00US$12.50US$0.992
Sep ’22US$4.85
US$18.75
+286.6%
33.3%US$25.00US$12.50US$1.472
Aug ’22US$5.22
US$18.75
+259.1%
33.3%US$25.00US$12.50US$1.372
Jul ’22US$5.78
US$18.75
+224.7%
33.3%US$25.00US$12.50US$2.302
Jun ’22US$5.14
US$18.75
+265.1%
33.3%US$25.00US$12.50US$2.262
May ’22US$5.73
US$18.75
+227.2%
33.3%US$25.00US$12.50US$2.392
Apr ’22US$7.11
US$18.75
+163.9%
33.3%US$25.00US$12.50US$2.882
Mar ’22US$7.01
US$12.50
+78.3%
0%US$12.50US$12.50US$2.441
Feb ’22US$8.09
US$12.50
+54.5%
0%US$12.50US$12.50US$2.601
Jan ’22US$3.83
US$12.50
+226.4%
0%US$12.50US$12.50US$2.721

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies